INDOCO REMEDIES LTD. - 532612 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
INDOCO REMEDIES RECEIVES TENTATIVE ANDA APPROVAL FROM USFDA FOR CANAGLIFLOZIN TABLETS06-12-2023
06-12-2023
INDOCO REMEDIES LTD. - 532612 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst/ Institutional Investors Meet under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201501-11-2023
INDOCO REMEDIES LTD. - 532612 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst/ Institutional Investors Meet under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201501-11-2023
INDOCO REMEDIES LTD. - 532612 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Transcript of Earnings Conference Call on Unaudited Financial Results (Standalone & Consolidated) for the quarter and half year ended 30-09-202323-10-2023
Indoco Remedies Share Price Live blog for 23 Oct 2023
Indoco Remedies stock price went down today, 23 Oct 2023, by -5.54 %. The stock closed at 351.05 per share. The stock is currently trading at 331.6 per share. Investors should monitor Indoco Remedies stock price closely in the coming days and weeks to see how it reacts to the news.23-10-2023
INDOCO REMEDIES LTD. - 532612 - Announcement under Regulation 30 (LODR)-Newspaper Publication
NEWSPAPER PUBLICATION OF UNAUDITED STANDALONE & CONSOLIDATED FINANCIAL RESULTS FOR THE QTR AND HALF YEAR ENDED 30-09-202320-10-2023
Indoco Remedies share price falls over 4%; should you buy or sell this stock? Here's what top brokerages say
In the last one year, Indoco Remedies share price has moved up by just half a per cent while the equity benchmark Sensex has gained nearly 11 per cent in the same period. Indoco Remedies reported a 13 per cent QoQ rise in its Q2FY24 standalone revenue.20-10-2023
INDOCO REMEDIES LTD. - 532612 - Disclosure Of Related Party Transactions Pursuant To Regulation 23(9) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015
Pursuant to Regulation 23(9) of SEBI LODR, Please find enclosed disclosure of related party transactions for the half year ended 30th September, 202319-10-2023
INDOCO REMEDIES LTD. - 532612 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio recording of Earnings Conference Call on Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended 30th September, 202319-10-2023
INDOCO REMEDIES LTD. - 532612 - Announcement Under Reg 30 Of SEBI LODR-USFDA Inspection
we hereby notify that pre-approval inspection was conducted by USFDA at the Company''s Solid Oral Formulation Facility Plant I located at Goa from October 12, 2023 to October 18, 2023.19-10-2023